contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö. 

Cyxone

Cyxone AB (publ), a biotech company in autoimmune diseases, has decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magnus Högerkorp, who will ensure a smooth...

<div class="abstract">Cyxone AB (publ), a biotech company in autoimmune diseases, has decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magnus Högerkorp, who will ensure a smooth transition.</div>Kjell was the CEO of Cyxone from when the company was founded in 2015 until 2019. He has thus good knowledge of Cyxone's projects, which facilitates a seamless change of management.Kjell holds a PhD in medical science, has held management positions in AstraZeneca R&amp;D including project inlicensing from biotech. Since 2001 he has worked in biotech and with corporate financing in Europe and North America."I and the board that took office in May 2023 have been strengthened in our view that there is considerable value in the company's two lead projects, and we are looking forward to realizing this with Kjell Stenberg at the helm and in close cooperation with our advisor Annika Espander (Asperion). I would also like to thank Carl-Magnus Högerkorp for his contributions to Cyxone since 2021", says Michael Oredsson, chairman of the board of Cyxone."I am very pleased to be given the opportunity to lead the development of the company's two drug candidates together with the Cyxone team. It is a privilege to be able to contribute to realizing the high potential value of the company's two projects, rabeximod and T20K. I will with high priority continue the development of rabeximod and its new salt formulation with initial priority on patients who don't respond well to biological disease modifying drugs, so called bioDMARDs. In parallel, we will also develop a clear plan for how to best optimize the value of our exciting T20K project in MS. Both projects are very interesting, and I see great possibilities to create great value for our shareholders in a cost-effective way", says Kjell Stenberg.ContactMichael Oredsson, Chairman of the Board Tel: +32 477026144 Email: michaeloredsson@gmail.comThis information is information that Cyxone AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 22 April 2024.About CyxoneCyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

Stay up to date with our newsletter